

LA POLIOMIELITIS HA SIDO ERRADICADA DE LAS AMÉRICAS
 El último caso con poliovirus salvaje fue detectado el 5 de septiembre de 1991, en Perú



Vigilancia de la Poliomielitis en las Américas

Cuadro No.1
Análisis de las muestras de heces de casos
Últimas 52 semanas (2011/17 - 2012/16)

| Lab. | País | Total* | SIN RESULTADOS | | | | AISLAMIENTO DE VIRUS | | | | | | | | |
|--------------|-------|-------------|----------------|----------|------------|------------|----------------------|-------------|-------------------|-------------|------------|-----------|--------------------|----------|----------|
| | | | Aún no en lab. | ≤14 días | 15-21 días | >21 días | % Aislamiento | Negativo | Otros Enterovirus | Otros Virus | Poliovirus | | | | |
| | | | | | | | | | | | Pendiente | Vacunal | Derivado de vacuna | Salvaje | |
| BEL | BRA | 5 | 0 | 0 | 0 | 0 | 0.0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CAR | DOM | 40 | 0 | 0 | 0 | 0 | 15.0 | 34 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| | GUY | 1 | 0 | 0 | 0 | 0 | 0.0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | HND | 72 | 33 | 0 | 0 | 0 | 12.8 | 34 | 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| | JAM | 6 | 0 | 0 | 0 | 1 | 0.0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | NIC | 23 | 0 | 0 | 0 | 0 | 13.0 | 20 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| | PAN | 8 | 0 | 0 | 0 | 0 | 12.5 | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | SLV | 1 | 0 | 0 | 0 | 0 | 0.0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CDC | GTM | 61 | 0 | 1 | 2 | 4 | 0.0 | 54 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | PRY | 15 | 2 | 0 | 0 | 0 | 23.1 | 10 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| | SLV | 51 | 0 | 0 | 0 | 0 | 5.9 | 48 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| FIO | BRA | 283 | 14 | 0 | 0 | 1 | 10.4 | 240 | 15 | 0 | 0 | 13 | 0 | 0 | 0 |
| | PER | 107 | 20 | 0 | 0 | 0 | 17.2 | 72 | 13 | 0 | 0 | 2 | 0 | 0 | 0 |
| IEC | BRA | 48 | 3 | 0 | 0 | 2 | 2.3 | 42 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| INDRE | MEX | 5 | 0 | 0 | 0 | 5 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| INS | COL | 133 | 0 | 0 | 0 | 0 | 4.5 | 127 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| | CRI | 41 | 0 | 0 | 0 | 0 | 2.4 | 40 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | ECU | 37 | 1 | 0 | 0 | 7 | 0.0 | 29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IPK | CUB | 23 | 2 | 0 | 0 | 0 | 0.0 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ISP | CHL | 71 | 0 | 0 | 0 | 0 | 1.4 | 70 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAL | ARG** | 290 | 1 | 0 | 0 | 119 | 24.7 | 138 | 12 | 0 | 10 | 20 | 0 | 0 | 0 |
| | BOL | 31 | 15 | 0 | 0 | 0 | 25.0 | 12 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| | URY | 3 | 0 | 0 | 0 | 0 | 0.0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | | 1355 | 91 | 1 | 2 | 139 | 10.6 | 1013 | 71 | 3 | 10 | 35 | 0 | 0 | 0 |

* Cada muestra se refiere a un individuo

** Datos en revisión en el sistema ISIS.

Muestras de casos solamente

Cuadro No.2
Poliovirus con diferenciación intratípica (ITD)
Últimas 52 semanas (2011/17 - 2012/16)

| Lab. | País | Casos AFP con ITD | | | Poliovirus pendiente de ITD | | | | | | | | | | | | Total | |
|--------------|------|-------------------|-----------|--------------|-----------------------------|----------|----------|----------|------------------------|----------|----------|----------|------------------------|----------|----------|----------|----------|----------|
| | | ≤7 días | Total | % | Aún no en el lab. | | | | En lab. < de 7 semanas | | | | En lab. > de 7 semanas | | | | | |
| | | | | | P1 | P2 | P3 | MIX | P1 | P2 | P3 | MIX | P1 | P2 | P3 | MIX | | |
| MAL | ARG | 4 | 10 | 40.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| MAL | URY | 0 | 2 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total | | 4 | 12 | 33.33 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |

Muestras de casos solamente



Cuadro No.1
Casos de parálisis flácida aguda bajo investigación
Según semana de notificación

| Sub Región | País | Total 2011 | Acum. 2012 | Semana | | | | | | | | |
|--------------|------|------------|------------|-----------|-----------|-----------|-----------|----------|----------|----------|----------|----------|
| | | | | 1-8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| AND | BOL | 7 | 8 | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | COL | 0 | 6 | 4 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| | ECU | 1 | 12 | 9 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| | PER | 10 | 20 | 17 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| | VEN | 0 | 9 | 2 | 2 | 1 | 0 | 2 | 2 | 0 | 0 | 0 |
| BRA | BRA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CAP | CRI | 7 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| | GTM | 1 | 7 | 0 | 0 | 1 | 3 | 0 | 1 | 2 | 0 | 0 |
| | HND | 6 | 27 | 15 | 5 | 1 | 1 | 1 | 3 | 0 | 0 | 1 |
| | NIC | 0 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| | PAN | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SLV | 1 | 6 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CAR | CAR | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LAC | CUB | 7 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| | DOM | 1 | 5 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 |
| | HTI | 10 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| MEX | MEX | 106 | 0 | 0 | 0 | 0 | 0 | 0 | ... | ... | ... | ... |
| NOA | CAN | 10 | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | ... |
| | USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| SOC | ARG | 6 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | CHL | 0 | 19 | 6 | 1 | 3 | 2 | 2 | 0 | 2 | 2 | 2 |
| | PRY | 4 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | URY | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| Total | | 177 | 136 | 77 | 13 | 14 | 11 | 6 | 6 | 4 | 4 | 3 |

Cuadro No.2
Casos de PFA notificados, tasa por 100,000 <15 años,
% de casos investigados dentro 48 horas, % con 1 muestra adecuada y % de unidades notificando semanalmente

| Sub Región | País | Polio 2012 | | Casos PFA e Indicadores 2012 Últ. 52 semanas (2011/17 - 2012/16) | | | | % Notificando | Polio 2011 | | Casos PFA e Indicadores 2011 (2011/01 - 2011/52) | | | | % Notificando |
|----------------|------|------------|------------|---|-------------|--------------------|-------------|---------------|------------|------------|---|-------------|--------------------|-------------|---------------|
| | | Confirmado | Compatible | Casos | Tasa | % Invest. <48 hrs. | %1 Muestra+ | | Confirmado | Compatible | Casos | Tasa | % Invest. <48 hrs. | %1 Muestra+ | |
| AND | BOL | 0 | 0 | 31 | 0.86 | 94 | 81 | 0 | 0 | 0 | 41 | 1.13 | 90 | 85 | ... |
| | COL | 0 | 0 | 139 | 1.06 | 55 | 81 | 0 | 0 | 0 | 157 | 1.20 | 62 | 82 | 91 |
| | ECU | 0 | 0 | 43 | 0.93 | 37 | 67 | 81 | 0 | 0 | 39 | 0.88 | 31 | 72 | 86 |
| | PER | 0 | 0 | 112 | 1.34 | 88 | 76 | 58 | 0 | 0 | 132 | 1.58 | 89 | 77 | 100 |
| | VEN | 0 | 0 | 61 | 0.71 | 77 | 80 | 0 | 0 | 0 | 71 | 0.83 | 72 | 85 | ... |
| BRA | BRA | 0 | 0 | 371 | 0.75 | 96 | 76 | 95 | 0 | 0 | 559 | 1.13 | 97 | 76 | 95 |
| CAP | CRI | 0 | 0 | 32 | 2.80 | 50 | 91 | 0 | 0 | 0 | 38 | 3.15 | 39 | 82 | ... |
| | GTM | 0 | 0 | 60 | 0.85 | 82 | 87 | 0 | 0 | 0 | 61 | 0.80 | 97 | 77 | ... |
| | HND | 0 | 0 | 72 | 2.10 | 86 | 92 | 179 | 0 | 0 | 63 | 1.80 | 81 | 92 | 94 |
| | NIC | 0 | 0 | 27 | 1.34 | 100 | 96 | 100 | 0 | 0 | 28 | 1.39 | 96 | 89 | 100 |
| | PAN | 0 | 0 | 8 | 0.80 | 75 | 63 | 80 | 0 | 0 | 9 | 0.90 | ... | ... | 87 |
| SLV | 0 | 0 | 53 | 2.22 | 55 | 83 | 0 | 0 | 0 | 59 | 2.44 | 51 | 78 | ... | |
| CAR | CAR | 0 | 0 | 26 | 0.54 | 88 | 15 | 67 | 0 | 0 | 25 | 0.59 | 76 | 16 | 99 |
| LAC | CUB | 0 | 0 | 25 | 1.24 | 100 | 92 | 100 | 0 | 0 | 32 | 1.58 | 100 | 94 | 100 |
| | DOM | 0 | 0 | 45 | 1.36 | 76 | 78 | 56 | 0 | 0 | 43 | 1.30 | 88 | 84 | 100 |
| | HTI | 0 | 0 | 2 | 0.05 | 0 | 100 | 0 | 0 | 0 | 10 | 0.17 | ... | 40 | ... |
| MEX | MEX | 0 | 0 | ... | ... | ... | ... | ... | 0 | 0 | 497 | 1.57 | 95 | 56 | 100 |
| NOA | CAN | 0 | 0 | 19 | 0.34 | NR | 37 | NR | 0 | 0 | 23 | 0.41 | ... | ... | ... |
| | USA | 0 | 0 | NR | NR | NR | NR | NR | 0 | 0 | NR | NR | NR | NR | NR |
| SOC | ARG | 0 | 0 | 129 | 1.24 | 37 | 81 | 104 | 0 | 0 | 168 | 1.64 | 30 | 83 | 107 |
| | CHL | 0 | 0 | 82 | 2.12 | 99 | 77 | 99 | 0 | 0 | 89 | 2.30 | 96 | 85 | 100 |
| | PRY | 0 | 0 | 18 | 0.90 | 44 | 67 | 0 | 0 | 0 | 18 | 0.90 | 50 | 67 | 93 |
| | URY | 0 | 0 | 5 | 0.65 | 0 | 60 | 4 | 0 | 0 | 9 | 1.17 | 11 | 67 | 4 |
| Total § | | 0 | 0 | 1360 | 0.81 | 72 | 78 | - | 0 | 0 | 2171 | 1.29 | 91 | 77 | 95 |

+ Tomado dentro de los primeros 14 días del inicio de parálisis

... - No datos

CAR incluye informes de todos sus países miembros

§ Excluyendo EUA

NR - No reportes